A Long-Term Non-Interventional Postmarketing Study to Assess Safety and Effectiveness of HUMIRA (Adalimumab) in Patients With Moderately to Severely Active Ulcerative Colitis (UC)

Status: Active, no longer recruiting

Phase of Trial: Phase IV

Latest Information Update: 19 Jun 2024

Price :

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

24 Jan 2022 Planned primary completion date changed from 6 Apr 2027 to 24 Jun 2030.
06 Jan 2021 Planned primary completion date changed from 24 Jun 2030 to 6 Apr 2027.
09 Jul 2020 Planned End Date changed from 6 Apr 2027 to 24 Jun 2030.

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com